Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesOtorhinolaryngology (ENT)Aetna Voice Therapy Coverage Update | OpenPayer
    Ask Trek AI about this page
    CurrentAetnaPolicy 0646

    Voice Therapy

    Customize your policy alerts

    Sign up for Aetna Policy 0646 alerts

    Get alerted when Policy 0646 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs Aetna's coverage and medical necessity criteria for voice therapy services for members, including indications considered medically necessary, not medically necessary, experimental/investigational uses, and related coding. It affects providers delivering speech-language pathology and otolaryngology services.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Policy Summary
    PayerAetna
    PolicyVoice Therapy
    Policy CodePolicy 0646
    Change TypeNo material change
    Effective DateSep 17, 2002
    Last ReviewSep 13, 2023
    Next Review DateJul 11, 2024
    Key ActionRe-evaluate the treatment plan if no clinical benefit is seen after 4 weeks of voice therapy.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    8Listed medically necessary indications
    4Re-eval interval (weeks)
    92507,92508Primary CPT codes
    6–10 / 6–12wTypical course (sessions/weeks)
    35CIVFMI cases identified

    Coverage Criteria for Voice Therapy

    Medically Necessary Indications

    Covered when ANY of the following indications are present:

    Indications: 1. Essential voice tremor; 2. Following surgery or traumatic injury to the vocal cords; 3. Following treatment for laryngeal (glottic) carcinoma; 4. Muscle tension dysphonia (functional dysphonia); 5. Paradoxical vocal cord motion; 6. Spastic (spasmodic) dysphonia; 7. Symptomatic benign vocal fold lesions (cysts, nodules and polyps); 8. Vocal cord paralysis.

    From policy medical necessity list.

    Not Medically Necessary Indications

    Not covered when ANY of the following indications are sole reason for therapy:

    Not Medically Necessary: 1. Improvement of voice quality; 2. Occupational or recreational purposes (e.g., public speaking, singing); 3. Self-limited conditions such as acute laryngitis; 4. Maintenance treatment when the member's symptoms are not improving; 5. Continued therapy beyond 4 weeks without meaningful clinical improvement.4 weeks re-evaluation

    Maintenance and cosmetic uses explicitly not medically necessary; voice feminization/masculinization for transgender individuals considered cosmetic (chunk 4).

    Experimental / Investigational

    Considered experimental/investigational (effectiveness not established):

    Experimental: 1. Pre-operative voice therapy to improve surgical outcomes for benign vocal fold lesions; 2. Vocal fold motion impairment following chemotherapy administration.

    Listed as experimental/investigational in policy.

    Coverage considerations and evidence tiers

    Summary of evidence-based coverage stance

    Comprehensive voice therapy supported when evidence shows benefit: Comprehensive voice therapy (combination of direct and indirect methods) has evidence of effectiveness versus no intervention for improving self-reported and observer-rated vocal functioning and instrumental assessments.evidence from multiple RCTs and systematic reviews

    Cochrane review identified benefit for combined therapy (chunks 32,33).

    Manual circumlaryngeal/manual laryngeal therapy: Manual therapies (MCT/CMT) and laryngeal manipulation show promising pre-post improvements in small pilot and retrospective studies, but randomized controlled trials and durability data are lacking.small uncontrolled studies or pilot designs

    Evidence limited; considered experimental/unproven in absence of higher-level trials (chunks 25,26).

    Resonant voice and specific voice training:

    Evidence summaries and clinical implications

    Evidence synthesis conclusions and clinical inferences reported in the document:

    Resonant voice and targeted voice therapies: Resonant voice therapy and related techniques have limited and generally low-to-moderate quality evidence; small studies report improvements in some acoustic and perceptual measures but larger, higher-quality RCTs are needed.

    Supports cautious use where clinically appropriate based on patient factors and therapist expertise.

    Voice therapy for benign vocal fold lesions: Voice therapy may improve patient-reported outcomes (e.g., VHI) and in some cases reduce the need for surgery (noted particularly for nodules and some polyps), but the evidence is heterogeneous and of variable quality; peri-operative voice therapy shows promise though intervention details are poorly reported.

    Consider a primary trial of voice therapy before surgery in selected patients; evidence insufficient to define a standardized protocol (chunks 41,46).

    Novafon local vibration therapy: Preliminary small studies reported improvements after short programs, but results are preliminary and require validation in larger studies.

    Experimental evidence—further validation needed.

    Evidence for voice therapy in pediatric vocal fold nodules

    Evidence summary relevant to coverage decisions

    Pediatric vocal fold nodules evidence: Systematic reviews identified limited and heterogeneous studies; 24 studies were reviewed with 8 reporting significant improvement after voice therapy and 5 reporting no significant change; methodological quality was variable and outcome measures were not standardized.

    Authors call for further well-designed RCTs and standardized outcome measures (chunks 54,55,56).

    Voice therapy used specifically to feminize a male-to-female transgender individual's voice or to masculinize a female-to-male transgender individual's voice is considered cosmetic and is not medically necessary.

    Portable voice amplifiers or megaphones (e.g., voice amplifiers) are not considered covered durable medical equipment and therefore are not covered under this policy.

    Interventions supported only by small, uncontrolled, pilot, or retrospective studies—such as many reports of manual circumlaryngeal therapy (MCT/CMT)—lack randomized controlled trial data and durability evidence; these approaches may be considered experimental/investigational or not covered until higher-quality controlled evidence is available.

    The evidence is insufficient to recommend voice therapy as a general treatment for symptomatic benign vocal fold lesions (cysts, nodules, polyps). Some lesions (e.g., vocal cysts) are unlikely to be cured by voice therapy alone and controlled trials comparing therapy with no intervention are lacking, so voice therapy cannot be broadly endorsed as a definitive treatment for these lesions.

    Included studies across reviews were heterogeneous in design and interventions and lacked standardized, validated outcome measures. This methodological heterogeneity limited comparability across studies and precluded pooled meta-analysis of results.

    Maintenance voice therapy when the member's symptoms are not improving is considered not medically necessary. If no clinical benefit is appreciated after 4 weeks of voice therapy, the treatment plan should be re-evaluated and continued therapy without meaningful improvement is not considered medically necessary.

    Voice training programs or therapeutic approaches requested for a specific indication that are not supported by controlled evidence, lack objective or validated outcome measures, or lack reported treatment fidelity may be considered not medically necessary or experimental for that requested indication.

    Coding and Billing

    Covered CPT Codes (if selection criteria met)CPTCovered
    92507Treatment of speech, language, voice, communication, and/or auditory processing disorder; individual [voice therapy]
    92508Treatment of speech, language, voice, communication, and/or auditory processing disorder; group, two or more individuals [voice therapy]
    Other related CPT CodesCPT
    31505-31592Laryngoscopy and laryngoplasty procedures (therapeutic)
    31611Construction of tracheoesophageal fistula and subsequent insertion of an alaryngeal speech prosthesis (e.g., voice button, Blom-Singer prosthesis)
    92521Evaluation of speech fluency
    92522Evaluation of speech sound production
    92523Evaluation of speech sound production with evaluation of language comprehension and expression
    92524Behavioral and qualitative analysis of voice and resonance
    92597
    Covered HCPCS Codes (home health/hospice)HCPCSCovered
    G0153Services performed by a qualified speech-language pathologist in the home health or hospice setting, each 15 minutes
    G0161Services performed by a qualified speech-language pathologist, in the home health setting, in the establishment or delivery of a safe and effective speech-language pathology maintenance program, each 15 minutes
    S9128Speech therapy, in the home, per diem
    HCPCS Codes Not Covered (for CPB indications)HCPCSNot Covered
    L8510Voice amplifier
    Other HCPCS Codes (related)HCPCS
    L8500Artificial larynx, any type
    L8505Artificial larynx replacement battery / accessory, any type
    L8507Tracheo-esophageal voice prosthesis, patient inserted, any type, each
    L8509Tracheo-esophageal voice prosthesis, inserted by a licensed health care provider, any type
    V5362Speech screening
    V5363Language screening
    Covered ICD-10 Codes (if selection criteria met)ICD-10Covered
    D14.1Benign neoplasm of larynx [benign vocal fold lesions]
    F44.4Conversion disorder with motor symptom or deficit [functional dysphonia]
    G25.2Other specified forms of tremor [voice]
    J38.00-J38.02Paralysis of vocal cords and larnyx
    J38.1Polyp of vocal cord and larynx
    J38.2Nodules of vocal cords
    R49.0Dysphonia [functional dysphonia]
    S19.83X+Other specified injuries of vocal cord
    ICD-10 Codes Not Covered (for CPB indications)ICD-10Not Covered
    A15.5Tuberculous laryngitis
    A36.2Laryngeal diphtheria
    A52.73Symptomatic late syphilis of other respiratory organs
    A69.1Other Vincent's infections [Vincent's angina]
    F64.1Gender identity disorder in adolescences and adulthood
    J02.0Streptococcal pharyngitis
    J04.0Acute laryngitis
    No explicit CPT/ICD codes listed in this sectionmixed
    No codes listed
    Re-evaluation interval
    Re-evaluation intervalIf no clinical benefit is appreciated after 4 weeks of voice therapy, the treatment plan should be re‑evaluated; further therapy is not considered medically necessary without meaningful improvement.
    Maintenance treatmentMaintenance treatment where the member's symptoms are not improving is considered not medically necessary.
    Threshold for continued therapyContinued therapy beyond 4 weeks without meaningful clinical improvement may be denied as not medically necessary.

    Provider Actions, Prior Authorization & Documentation

    Prior Authorization

    Prior authorization / coverage for primary voice therapy codes

    CPT codes 92507 (individual voice therapy) and 92508 (group voice therapy) and specified home-health speech codes (e.g., G0153, G0161, S9128) are covered when the policy’s selection criteria are met; verify that the indication meets medical necessity before billing.

    • 92507 — Treatment of speech, language, voice, communication, and/or auditory processing disorder; individual
    • 92508 — Treatment of speech, language, voice, communication, and/or auditory processing disorder; group, two or more individuals
    • G0153, G0161, S9128 — specified home-health/hospice speech therapy codes
    Prior Authorization

    Prior authorization may be needed for intensive or post‑surgical rehab

    Prior authorization may be appropriate when voice therapy is requested as post-treatment rehabilitation after early glottic carcinoma or for prolonged/intensive manual circumlaryngeal therapy; include prior documentation of diagnosis and prior conservative measures.

    Background and Scope

    Voice disorders such as vocal cord paralysis, benign lesions (nodules and polyps), and functional conditions like muscle tension dysphonia (MTD) can impair voice production and communication. Diagnosis typically involves an otolaryngologic evaluation including history, voice assessment, and laryngoscopic visualization. Treatment options include behavioral voice therapy (direct and indirect techniques), medical interventions, and surgery depending on etiology; for nodules, a typical conservative therapy course is often reported as approximately 6–10 sessions over 6–12 weeks.

    Definitions

    Muscle tension dysphonia (MTD)
    DefinitionMuscle tension dysphonia (MTD) is a functional voice disorder characterized by excessive tension of the (para)laryngeal musculature leading to disturbed vocal fold behavior.
    EtiologyEtiologic factors include psychological/personality factors, vocal misuse/abuse, and compensation for underlying disease (e.g., reflux, infection, organic lesions).
    Treatment contextEffective treatment options include indirect therapy (vocal hygiene/education), direct voice therapy, circumlaryngeal manual therapy (CMT), medical treatment, and surgery for secondary lesions; management is multidisciplinary with laryngologist and SLP collaboration.
    Paradoxical vocal fold motion
    DefinitionParadoxical vocal fold motion is abnormal adduction of the vocal cords during respiration (especially inspiration) producing laryngeal airflow obstruction.
    Clinical presentation
    Policy Summary
    PayerAetna
    PolicyVoice Therapy
    Policy CodePolicy 0646
    Change TypeNo material change
    Effective DateSep 17, 2002
    Last ReviewSep 13, 2023
    Next Review DateJul 11, 2024
    Key ActionRe-evaluate the treatment plan if no clinical benefit is seen after 4 weeks of voice therapy.
    SourceLink
    On This Page
    Coverage Criteria for Voice TherapyCoding and BillingProvider Actions, Prior Authorization & DocumentationBackground and ScopeDefinitions
    Resonant voice training and targeted programs (e.g., Vocal Function Exercises, Comprehensive Voice Rehabilitation Program) have RCT or controlled evidence showing benefit; trials often show both active treatments effective though comparative superiority may be unclear.
    RCT-level evidence exists though comparative benefit may be similar

    Pedrosa RCT and systematic reviews report positive outcomes (chunks 34,33).

    Post-treatment voice rehabilitation: Voice therapy is effective for rehabilitation after early glottic carcinoma with randomized evidence showing improvement in patient-reported and acoustic measures.RCT evidence

    Randomized trial evidence supports post-glottic carcinoma therapy (chunk 29).

    Paradoxical vocal fold motion management: Primary treatment involves vocal cord relaxation techniques and breathing exercises; voice therapy is a mainstay when diagnosis is confirmed by laryngoscopy and pulmonary function testing.clinical diagnostic confirmation

    Diagnosis and management descriptions support therapy role (chunk 30).

    Therapies for sulcus vocalis and glottal gap: Direct voice therapy aims to improve vocal efficiency in sulcus vocalis; some techniques (e.g., lip trills) can reduce glottal gap in selected patients though evidence is limited.

    May be used as initial or adjunctive therapy; limited evidence.

    Chemotherapy-induced vocal fold motion impairment (CIVFMI): CIVFMI is rare; airway compromise can occur and spontaneous resolution after stopping the offending agent is common; management may require early identification and cessation of the agent and sometimes surgical airway interventions.

    Limited case reports inform management decisions.

    Pediatric vocal fold nodules: Systematic reviews report some evidence supporting voice therapy for children with vocal fold nodules but studies vary in design and quality; overall findings are suggestive but not definitive.

    Voice therapy is generally recommended as the preferred therapeutic option for pediatric VFNs, though higher-quality trials are needed (chunks 54,55).

  1. Include documentation of diagnosis and prior conservative measures when requesting authorization for intensive or post-surgical rehabilitation
  2. Evidence supports voice therapy for rehabilitation after early glottic carcinoma (van Gogh RCT)
  3. Prior Authorization

    No explicit additional prior authorization requirements specified

    This policy excerpt does not specify any additional explicit prior authorization requirements or unique prior‑auth triggers beyond standard verification of medical necessity for voice therapy codes.

    • No procedure‑specific prior authorization rules are listed in this section
    Prior Authorization

    Prior authorization (not specified in policy history excerpt)

    The policy history and review notes in the document excerpt do not list specific procedure codes or explicit prior authorization statements; use plan-specific prior‑auth processes as applicable.

    • Policy history shows last review 09/13/2023 and effective date 09/17/2002
    Denial Risk

    Re‑evaluate therapy if no clinical benefit at 4 weeks

    If no clinical benefit is observed after 4 weeks of voice therapy, re-evaluate the treatment plan; continued therapy without meaningful improvement may be denied as not medically necessary.

    • Re-evaluate at 4 weeks; further therapy considered not medically necessary without meaningful improvement
    • Maintenance treatment where symptoms are not improving is not medically necessary
    Step Therapy

    Sequence conservative combined voice therapy before experimental or invasive options

    Consider a trial of conservative voice therapy (combination of direct and indirect techniques) before proceeding to more invasive or experimental interventions when evidence supports it.

    • Cochrane and systematic reviews support combined direct + indirect therapy versus no intervention
    • Manual therapies have limited evidence and may be considered after conservative approaches
    Step Therapy

    Step therapy consideration for benign vocal fold lesions (attempt voice therapy first in selected cases)

    Some evidence and expert opinion suggest attempting voice therapy (pre‑operative or as primary treatment) for symptomatic benign vocal fold lesions may avoid surgery in selected cases; literature is heterogeneous and does not define a required step‑therapy protocol.

    • Voice therapy may improve perceived voice quality and in some cases avoid surgery for benign vocal fold lesions
    • No formal step‑therapy rules are specified in the policy
    Step Therapy

    No formal step‑therapy rules specified

    No formal step therapy rules are defined in this policy excerpt; clinical review sections summarize evidence for effectiveness but do not establish mandatory step protocols.

    • Systematic reviews report heterogeneous evidence for pediatric vocal fold nodules and adult interventions
    • Policy does not mandate a specific step‑therapy sequence
    Documentation Required

    Perform otolaryngologic evaluation including laryngoscopy before/with therapy

    An otolaryngologic evaluation (history, focused voice assessment and endoscopic laryngoscopy) is described as part of diagnosis and typical assessment prior to or alongside voice therapy.

    • Otolaryngologist performs history, voice listening, and endoscopic (endoscope) visualization of vocal cords
    • SLP assessments (e.g., acoustic spectrograph) may document voice strengths and weaknesses
    Documentation Required

    Document diagnosis, prior treatments, objective and patient‑reported outcome measures

    Document the diagnosis, prior treatments, objective measures and patient‑reported outcomes to support medical necessity for voice therapy requests and ongoing coverage decisions.

    • Include diagnosis (e.g., MTD, UVFP, paradoxical vocal fold motion, BVFL), prior conservative treatments, and planned therapy type/number of sessions
    • Provide objective and patient‑reported outcomes (VHI, V-RQOL, acoustic/perceptual measures) pre‑ and post‑therapy
    Documentation Required

    Collect multi‑dimensional assessment documentation (VHI, VHI‑10, video‑stroboscopy, perceptual/acoustic ratings)

    Use multi‑dimensional assessment protocols where available (self‑assessment scales such as VHI or VHI‑10, video‑stroboscopy, perceptual, aerodynamic and acoustic ratings) to document baseline status and response to therapy.

    • Recommended measures referenced include VHI, VHI‑10, V-RQOL, videostroboscopy, perceptual and acoustic ratings
    • Pre‑ and post‑therapy measurements strengthen documentation of clinical benefit
    Denial Risk

    Voice feminization/masculinization for transgender individuals is not covered

    Voice therapy to feminize male‑to‑female or masculinize female‑to‑male transgender individuals is considered cosmetic and is not covered; do not bill these services as medically necessary.

    • Policy explicitly states these gender‑affirming voice therapy uses are not medically necessary
    • Related CPB 0615 (Gender Affirming Surgery) referenced for context
    Denial Risk

    Evidence limitations may lead to denial for experimental/unproven interventions

    Interventions lacking controlled evidence, those supported only by small uncontrolled or pilot studies (e.g., many reports of manual circumlaryngeal therapy), or those without durable outcome data may be considered experimental/investigational and denied; include strong diagnostic and outcome documentation if requesting coverage.

    • Manual laryngeal therapies have limited evidence and are often from small uncontrolled studies
    • Policy classifies certain indications (pre‑operative therapy for benign lesions, chemotherapy‑related vocal fold motion impairment) as experimental/investigational
    Denial Risk

    Denial risk for maintenance therapy without improvement after 4 weeks

    If symptoms are unchanged after 4 weeks of therapy, continued maintenance therapy may be considered not medically necessary and subject to denial; document objective and patient‑reported lack of improvement when making coverage decisions.

    • Maintenance treatment without improvement is not medically necessary
    • Re‑evaluate and document outcomes at the 4‑week interval
    Note

    Administrative note: CPBs guide but do not guarantee coverage

    Clinical Policy Bulletins are administrative tools to assist benefit administration and do not themselves guarantee coverage; final coverage determinations remain subject to plan provisions.

    • Use CPB guidance alongside plan benefit language when making coverage decisions
    Note
    Note
    Frequently mimics persistent asthma; flow‑volume loops often show inspiratory loop flattening during symptoms and diagnosis is confirmed by direct rhinolaryngoscopy showing posterior glottic chink with anterior adduction.
    Primary treatmentMainstay of treatment involves teaching vocal cord relaxation techniques and breathing exercises.
    Adductor spasmodic dysphonia (ADSD)
    DefinitionAdductor spasmodic dysphonia (ADSD) is a disabling voice disorder characterized by involuntary disruptions of phonation due to laryngeal muscle spasms.
    Typical managementBotulinum toxin injections to the thyroarytenoid muscles are the treatment of choice for ADSD; some patients may benefit from adjunct injections targeting supraglottic hyperadduction.
    Role of speech therapySpeech therapy may be used adjunctively to address compensatory behaviors, but botulinum toxin is primary intervention for many patients.
    Manual circumlaryngeal therapy (MCT/CMT)
    DefinitionManual circumlaryngeal therapy (MCT/CMT) comprises manual laryngeal musculoskeletal tension‑reduction techniques involving focal palpation and circum‑laryngeal massage to reduce extralaryngeal muscle hypertonicity.
    Evidence contextPublished reports include small pilot and pre‑post studies reporting improvements in perceptual and acoustic measures, but studies lack control groups and durability data.
    Clinical roleMay be used as part of direct therapy for muscle tension dysphonia in multidisciplinary care, though randomized controlled trials and long‑term outcomes are limited.
    Sulcus vocalis
    DefinitionSulcus vocalis is a groove along the free edge of the vocal fold that disrupts the pliable vocal fold cover and alters the intrinsic mucosal wave.
    Impact on voiceCauses breathy, effortful dysphonia and reduced vocal efficiency due to altered mucosal wave and vibratory characteristics.
    Therapeutic goalPrimary speech therapy goal is to improve vocal efficiency; direct voice therapy is the most commonly employed method and may be combined with amplification and behavioral changes to reduce vocal fatigue.
    Hyperkinetic dysarthria / essential voice tremor context
    DefinitionHyperkinetic dysarthria and essential voice tremor are disorders characterized by abnormal involuntary movements affecting respiratory, phonatory, and articulatory structures, leading to impaired speech and deglutition.
    SLP evaluationStandard SLP evaluation includes case history, cranial nerve/motor assessment of speech structures, speech characteristic evaluation, and patient‑reported impact on activities of daily living.
    Management approachSLP management includes behavioral and compensatory strategies to address compromised speech and intelligibility; swallowing disorders are managed based on individual pathophysiology.
    Voice therapy
    DefinitionVoice therapy comprises behavioral interventions—direct and indirect—aimed at improving voice function in disorders such as vocal fold nodules, dysphonia (including MTD), paradoxical vocal fold motion, and vocal cord paralysis.
    Examples of techniquesIncludes direct methods (resonant voice, vocal function exercises, circumlaryngeal therapy) and indirect methods (vocal hygiene, patient education, breath support training).
    Clinical applicationRecommended as the preferable therapeutic option for pediatric vocal fold nodules and used for rehabilitation after surgery or injury when indicated; treatment courses commonly span multiple sessions over weeks depending on indication and response.